Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
By S. Potkin, A. Saha, M. Kujawa, W. Carson, Mirza W. Ali, E. Stock, J. Stringfellow, G. Ingenito, S. Marder. Archives of General Psychiatry, 2003
623 citations recorded by the source corpus.
Subfields: Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/850a97598ddc026d77952e3bcb29b9d27745ac8d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Psychiatry and Mental health
Citations in the corpus
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, background): “From that point onwards, further RCTs, open-label studies and meta-analyses have been conducted showing that aripiprazole is effective in the treatment of acute episodes of schizophrenia (Category of Evidence A, Recommendation grade 1) (Bhattacharjee and El-Sayeh 2008; Cutler et al. 2006; El-Sayeh a”